IP Library Granted Patent US 9,353,116
Granted Patent B2
US 9,353,116 · App. 13/690,785 · Granted May 31, 2016

Methods and compositions for kinase inhibition

Inventors: Adam L. Garske (San Francisco, CA); Kevan M. Shokat (San Francisco, CA)
Assignee: The Regents of the University of California
C07D487/04C07D239/94C07D403/12C07D409/12C12N9/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,353,116
App. No.
13/690,785
Granted
May 31, 2016
Kind
B2
Abstract

The present invention sets forth a new chemical genetic approach for engineering kinase enzymes with a cysteine gatekeeper residue as well as for developing electrophilic inhibitors thereto. The present invention also provides a Src proto-oncogenic tyrosine kinase with a cysteine gatekeeper that recapitulates wild type activity and can be irreversibly inhibited both in vitro and in cells. The present invention also provides methods and compositions for modulating kinases and for treating kinase-associate diseases.

Claims (34)

1. A compound having the formula:

wherein:

X is ═N—;

Ring A is phenyl;

L 1 is a bond;

L 2 is a bond;

L 3 is —C(O)—, —S(O) 2 —, or —NHS(O) 2 —;

L 4 is unsubstituted C 1 -C 5 alkylene;

R 1 is hydrogen or —NH 2 ;

R 2 is substituted or unsubstituted alkyl or substituted or unsubstituted cycloalkyl;

R 3 is substituted or unsubstituted alkyl;

a is 1;

b is 1;

and

the salts and isomers thereof.

2. The compound of claim 1 , wherein

L 3 is —C(O)—, —S(O) 2 —, or —NHS(O) 2 —;and

R 3 is unsubstituted alkyl or alkyl substituted with chloro, fluoro, methyl, difluoromethyl, or trifluoromethyl.

3. The compound of claim 2 , wherein R 3 is ethenyl, ethyl, 2,2,2-trichloroethyl, 2,2-dichloroethyl, 2-chloroethyl, 2,2,2-trifluoroethyl, 2,2-difluoroethyl, or 2-fluoroethyl, propyl, isopropyl, 1-propenyl, or 2-propenyl.

4. The compound of claim 3 , wherein -L 3 -R 3 is:

5. The compound of claim 1 , wherein,

L 1 is a bond; and

R 1 is hydrogen.

6. The compound of claim 1 , wherein

L 1 is a bond; and

R 1 is NH 2 .

7. The compound of claim 1 , wherein

L 2 is a bond; and

R 2 is methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, cyclopentyl, hexyl, or cyclohexyl.

8. The compound of claim 7 , wherein R 2 is isopropyl or cyclopentyl.

9. The compound of claim 8 , wherein R 2 is isopropyl.

10. The compound of claim 8 , wherein R 2 is cyclopentyl.

11. A compound, having the formula:

12. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2013
From: GARSKE, ADAM L.; SHOKAT, KEVAN M.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 029791/0217 →
CONFIRMATORY LICENSE Recorded Jan 8, 2013
From: UNIVERSITY OF CALIFORNIA SAN FRANCISCO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029587/0265 →
Continuity (3)
Continuation PCTUS2011039347 · Jun 6, 2011
Provisional Application 61351663 · Jun 4, 2010
Related Publication 20130137708A1 · May 30, 2013